Rifaximin Improves Frailty in Patients with Decompensated Cirrhosis: A Randomized Trial

Area of Science:

• Hepatology
• Gastroenterology
• Clinical Pharmacology

Background:

• Decompensated cirrhosis is associated with high rates of frailty, increasing morbidity and mortality.
• Frailty assessment in cirrhosis is crucial for predicting outcomes.

Purpose of the Study:

• To evaluate the impact of six-month Rifaximin therapy on frailty in patients with decompensated cirrhosis.
• To assess Rifaximin's effect on disease severity, inflammatory markers, and hospitalization rates.

Main Methods:

• A randomized controlled trial involving 100 patients with decompensated cirrhosis and frailty (Liver Frailty Index > 4.5).
• Patients received standard medical therapy (SMT) plus Rifaximin (rSMT) or SMT alone for six months.
• Primary outcome was frailty improvement; secondary outcomes included CTP/MELD scores, inflammatory markers, hospitalization, and survival.

Main Results:

• Rifaximin significantly improved frailty (P < 0.001) and disease severity (CTP and MELD scores, P < 0.05).
• The intervention group showed reduced MELD scores (-2.3 ± 2.9) and lower IL-6 levels (P = 0.01).
• Hospitalizations decreased significantly in the Rifaximin group (16% vs 52%, P < 0.001), with a trend towards lower mortality (10% vs 22%).

Conclusions:

• Rifaximin therapy is effective in improving frailty and disease severity in decompensated cirrhosis.
• Rifaximin therapy leads to a significant reduction in hospitalization rates.
• Further research may explore Rifaximin's role in improving long-term outcomes in this patient population.